Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 2,092 shares of the stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $18.01, for a total transaction of $37,676.92. Following the completion of the transaction, the chief executive officer now owns 204,069 shares […]
HC Wainwright started coverage on shares of Entrada Therapeutics (NASDAQ:TRDA – Get Rating) in a research note published on Monday, Marketbeat.com reports. The firm issued a buy rating and a $25.00 target price on the stock. HC Wainwright also issued estimates for Entrada Therapeutics’ Q1 2023 earnings at ($0.84) EPS, Q2 2023 earnings at ($0.91) […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating)’s share price rose 5.2% on Thursday . The stock traded as high as $17.25 and last traded at $16.78. Approximately 32,295 shares were traded during trading, a decline of 32% from the average daily volume of 47,732 shares. The stock had previously closed at $15.95. Wall Street Analyst […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating)’s share price shot up 5.2% on Thursday . The stock traded as high as $17.25 and last traded at $16.78. 32,295 shares were traded during mid-day trading, a decline of 32% from the average session volume of 47,732 shares. The stock had previously closed at $15.95. Entrada Therapeutics […]
Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) were up 5.2% during trading on Thursday . The company traded as high as $17.25 and last traded at $16.78. Approximately 32,295 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 47,732 shares. The stock had previously closed at […]